Stay updated on Durvalumab and Tremelimumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab and Tremelimumab in NSCLC Clinical Trial page.

Latest updates to the Durvalumab and Tremelimumab in NSCLC Clinical Trial page
- Check6 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3. No user-facing content or functionality changes are introduced.SummaryDifference0.1%

- Check13 days agoChange DetectedLatest history entry adds Contacts/Locations and Study Status to the study record. A deletion was recorded on 2025-09-16.SummaryDifference0.3%

- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedAdded a new revision entry 'Revision: v3.4.2' to the version history. Removed the government funding lapse notice; these changes do not affect the study record content.SummaryDifference0.4%

- Check41 days agoChange DetectedAdded a site-wide notice about potential delays due to a lapse in government funding and the NIH Clinical Center’s open status, and updated the page revision to v3.4.1 (replacing v3.4.0).SummaryDifference0.4%

- Check48 days agoChange DetectedUI updates add a Show glossary option and explain color-coding for additions/deletions (green/red), and the page revision label shifts from v3.3.4 to v3.4.0 with capitalization tweaks in 'No FEAR Act data'.SummaryDifference0.5%

- Check62 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 on the Record History page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Durvalumab and Tremelimumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab and Tremelimumab in NSCLC Clinical Trial page.